Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $42 Price Target

Author: Benzinga Newsdesk | March 11, 2024 10:12am
JMP Securities analyst Jonathan Wolleben reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and maintains $42 price target.

Posted In: PTGX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist